Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
anticonvulsant/accident vasculaire cérébral
Le lien est enregistré dans le presse-papiers
Page 1 de 17 résultats
.DELTA.2-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to the drug potential of anticonvulsants in the treatment of stroke, particularly, several .DELTA..sup.2 -1,2,3-triazoline and aminoalkylpyridine (AAP) anticonvulsants that seem to work by impairing the excitatory amino acid (EAA) L-glutamate (L-Glu)
Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of neurodegeneration in pathological conditions such as stroke, cerebral ischaemia, cerebral palsy, hypoglycaemia, epilepsy, Alzheimer's disease,
Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This invention relates to pharmaceutical compounds, some of which are novel, and to their anticonvulsant, sedative and neuroprotective properties.
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of
Anticonvulsant compound
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national phase under 35 U.S.C. .sctn. 371 of PCT International Application No. PCT/GB2015/052624, which has an international filing date of Sep. 10, 2015 and designated the United States of America, which application claims benefit
Valproyltaurinamide derivatives as anticonvulsant amd CNS active agents
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to new derivatives of valproic acid and taurine, a method for their preparation and use for thereof for the treatment of epilepsy, neurological, affective and psychotic disorders as well as for the treatment of pain and migraine.
BACKGROUND OF THE
Arylalkyl-amines having anticonvulsant and neuroprotective properties
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This invention relates to pharmaceutical compounds, some of which are novel, and to their anticonvulsant, sedative and neuroprotective properties.
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of
Arylalkyl-amines having anticonvulsant and neuroprotective properties
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This invention relates to pharmaceutical compounds, some of which are novel, and to their anticonvulsant, sedative and neuroprotective properties.
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of
Use of conantokins
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which include preferably one to two or more
Use of conantokins
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturaly available peptides, and which include preferably one to two or more
Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Compounds of formula I: ##STR2##
are structurally novel anticonvulsants (Maryanoff, B. E., Costanzo, M. J., Nortey, S. O., Greco, M. N., Shank, R. P., Schupsky, J. J., Ortegon, M. E., and Vaught, J. L. J. Med. Chem. 1998, 41, 1315-1343), found to possess anticonvulsant
Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to therapeutically active quinolinic sulfide derivatives acting as potent and specific antagonists of excitatory amino acids, to a process for preparation and to their use in treatment in neurological disorders.
Particularly, the compounds
Neurotherapeutic azole compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention is directed to neurotherapeutic azole compounds containing a carbamoyl group which are useful as anticonvulsant agents.
DESCRIPTION OF THE PRIOR ART
Many reports have disclosed that arylalkyl azole compounds are effectively used as anticonvulsant,
Novel arylcycloalkanepolyalkylamines
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF INVENTION
1. Field of the Invention
This invention relates to novel arylcycloalkanepolyalkylamines that are useful as anti-psychotic, anti-ischemia, anti-stroke, anti-dementia and anti-convulsant agents. In particular, this invention relates to arylcycloalkanepolyalkylamines that are
Arylcycloalkanepolyalkylamine ligands
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF INVENTION
1. Field of the Invention
This invention relates to novel arylcycloalkanepolyalkylamines that are useful as antipsychotic, anti-ischemia, anti-stroke, anti-dementia and anti-convulsant agents. In particular, this invention relates to arylcycloalkanepolyalkylamines that are
Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
NMDA AMPA Receptors
Excessive excitation by neurotransmitters can cause the degeneration and death of neurons. It is believed that this degeneration is in part mediated by the excitotoxic actions of the excitotoxic amino acids (EAA) glutamate and aspartate at the
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
